SONOSCAPE(SZ:300633) Xin Lang Cai Jing·2026-01-07 01:31Core Viewpoint - The financial performance and trading activity of Kaili Medical indicate a mixed outlook, with revenue growth but significant decline in net profit, alongside notable changes in shareholder composition and trading volumes [1][2][3]. Group 1: Financial Performance - For the period from January to September 2025, Kaili Medical reported operating revenue of 1.459 billion yuan, representing a year-on-year increase of 4.37% [2]. - The net profit attributable to shareholders was 33.51 million yuan, showing a significant year-on-year decrease of 69.25% [2]. - Cumulative cash dividends since the company's A-share listing amount to 381 million yuan, with 258 million yuan distributed over the past three years [3]. Group 2: Trading Activity - On January 6, Kaili Medical's stock price remained unchanged, with a trading volume of 146 million yuan [1]. - The financing buy-in amount for the day was 19.69 million yuan, while the financing repayment was 13.77 million yuan, resulting in a net financing buy of 5.92 million yuan [1]. - The total balance of margin trading as of January 6 was 169 million yuan, with the financing balance accounting for 1.41% of the circulating market value, indicating a high level compared to the past year [1]. Group 3: Shareholder Composition - As of September 30, 2025, the number of shareholders increased to 16,100, a rise of 12.75% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.31% to 26,824 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 7.40 million shares, an increase of 1.72 million shares, while the Hua Bao Zhong Zheng Medical ETF reduced its holdings by 1.07 million shares [3].